Loading
Life sciences · Journal article
The Oncologist · September 25, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Background The incidence of early-onset colorectal cancer (EOCRC) is rising globally, presenting unique clinical challenges due to its aggressive nature compared to late-onset cases. While obesity is a known risk factor for carcinogenesis, its prognostic significance specifically on the EOCRC population remains underexplored. We hypothesized that the association of metabolic dysregulation with tumor aggressiveness and survival may depend on the age of onset. Methods A total of 324 patients with stage II/III rectal cancer from the FOWARC trial were stratified by BMI (using the Asian overweight cut-off of 24 kg/m²) and age of onset (early-onset <50 years vs. late-onset ≥50 years). The clinicopathologic characteristics, treatment response, complications, and survival outcomes were compared. Results The prognostic profile was heterogeneous between patients with high and low BMI. Notably, age had opposing prognostic value in the two groups. In the early-onset subgroups, patients with high BMI exhibited more prevalent aggressive phenotypes, including T4 stage, MRF+, elevated tumor length/thickness, and pretreatment CEA. However, in the late-onset subgroups, those phenotypes were less in the patients with high BMI. For short-term outcome, the incidence of pathological complete response after neoadjuvant treatment and complications was similar between two groups. In the early-onset subgroups, the overall (P = 0.003) and disease-free (P = 0.001) survival outcomes were significantly worse in the patients with high BMI compared to those with low BMI. However, this difference was not observed in the late-onset subgroups. Conclusion The association of overweight and obesity with aggressive tumor phenotypes and poor survival outcomes is specifically observed in early-onset rectal cancer, which highlights the need for BMI-specific therapeutic strategies and weight management interventions in these vulnerable cases.